Eris Lifesciences shares jump 6% after Motilal Oswal initiates coverage with 'buy' tag
We expect a 17% earnings CAGR for Eris over FY2124 versus marginal earnings growth during FY1821, driven by higher scope of penetration of technically superior drugs in AD therapy, Motilal Oswal said28-12-2021